查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542903

全球介入性心臟病學市場 - 2024-2031

Global Interventional Cardiology Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場規模

2023年，全球介入性心臟病學市場規模達到144.7億美元，預計到2031年將達到286.7億美元，2024-2031年預測期間複合年成長率為9.1%。

根據美國醫學會的規定，介入性心臟病學是心臟病學中的一個醫學分支，它藉助專門的影像和其他診斷技術來評估冠狀動脈和心室的血流和壓力，也涉及所使用的技術程序和藥物對於那些損害心血管系統功能的異常。

介入性心臟病學市場動態

心血管疾病病例的不斷增加、老年人口、生活方式的改變以及人們對心血管疾病的認知不斷提高，正在推動全球介入性心臟病學市場的成長。

新產品的推出將在預測期內推動全球介入性心臟病學市場的發展。

新產品的推出推動了全球介入性心臟病學市場的成長。例如，2021 年 6 月，美國食品藥物管理局批准雅培的 XIENCE 系列支架用於美國高出血風險 (HBR) 患者的為期一個月的雙抗血小板治療 (DAPT)。同樣，2020 年 5 月，飛利浦影像導引治療公司的 Reconnaissance PV .018 OTW 數位 IVUS 導管獲得美國 FDA 510 (K) 批准。同樣，2021 年3 月，美敦力(Medtronic) 的Harmony 經導管肺動脈瓣(TPV) 獲得美國食品和藥物管理局的產品批准，這是首個用於治療典型右心先天性心臟病患者的微創療法。

此外，2021 年 6 月，雅培的 Amplatzer Piccolo 封堵器在印度推出。它是世界上第一個透過微創手術植入最小嬰兒（重量僅 700 克）的醫療設備，用於治療動脈導管未閉 (PDA)。此外，2021年7月，私人醫療技術公司MedAlliance推出了兩款高性能球囊ORIGIN SC和ORIGIN NC，用於為患有危及生命的冠狀動脈和周邊動脈疾病的患者進行血管準備。因此，新產品的推出將在預測期內推動全球介入性心臟病學市場。

嚴格的法規和高昂的成本阻礙了全球介入性心臟病學市場的成長。

然而，心臟病介入的高昂成本和嚴格的監管將在預測期內阻礙全球介入心臟病學市場。例如，美國 FDA 正在修訂兩份針對發明新型冠狀動脈、周邊血管和神經血管導絲的供應商的指導文件。 FDA 於 2018 年 6 月報告了該文件草案，但尚未收集對其中一份文件的評論。這些文件預計將涵蓋性能測試、推薦標籤和潤滑塗層，這將為行業和FDA 工作人員提供關於評估上市前批准申請（PMA）中提交的導管、導絲和輸送系統性能的最不嚴格的方法的建議。此外，慢性完全阻塞的經皮冠狀動脈介入治療的平均成本為 14,946 ± 7,699 美元，使得大多數人無法進行手術，從而減緩了預測期內全球介入心臟病學市場的成長。

COVID-19 影響分析

COVID-19 大流行損害了全球介入性心臟病學市場，因為在大流行期間，介入性心臟病學手術大幅下滑。例如，英國心血管介入學會對大流行封鎖期間在英國進行的所有經皮冠狀動脈介入治療 (PCI) 進行了回顧性分析，並與大流行前時期的 PCI 數量進行了比較。

回顧性分析得出的結論是，PCI 減少了 49%，其中穩定型心絞痛受影響最嚴重，減少了 66%，而 ST 段抬高型心肌梗塞 (STEMI) 的 PCI 減少了 33%。此外，疫情改變了人們對健康生活方式選擇的看法，導致心血管疾病病例減少，從而對全球介入性心臟病學產生了負面影響。

介入性心臟病學市場細分分析

預計在預測期內（2024-2031 年）支架的需求量將會很大。

由於全球介入性心臟病學市場的新推出和產品批准，預計在預測期內（2024-2031年），支架將主導全球介入心臟病學市場。例如，2021年8月，SINOMED與愛爾蘭國立戈爾韋大學（NUI Galway）合作，在歐洲推出了HT Supreme塗藥支架（DES），並在戈爾韋大學醫院進行了首次商業植入。同樣，2022 年 5 月，美國食品藥物管理局 (FDA) 批准了美敦力公司的 Onyx Frontier 藥物洗脫支架 (DES)。 Onyx Frontier DES 利用與 Resolute Onyx DES 相同的支架平台以及增強的輸送系統。

同樣，2021 年 1 月，FDA 批准了 Boston Scientific 的 Synergy Megatron 藥物洗脫支架，旨在治療主動脈附近的大近端支架。此外，2021 年 5 月，Alvimedica 的一種新型無聚合物自膨式 Amphilimus 洗脫支架 NiTiDES 獲得了 CE 標誌，該支架用於治療股淺動脈 (SFA) 病變。因此，從上述資料來看，預計支架將在整個預測期內主導全球介入性心臟病學市場。

介入性心臟病學市場地域佔有率

預計北美將主導全球介入性心臟病學市場。

由於心血管疾病病例的增加以及該地區主要市場參與者的存在，預計北美在預測期內（2023-2031年）將擁有一個巨大的市場。根據 CDC 統計，每 34 秒就有一名美國人死於心血管疾病。 2020年，心血管疾病導致超過697,000人死亡。此外，雅培、愛德華茲生命科學公司、波士頓科學公司、強生、美敦力和庫克醫療公司等主要市場參與者的存在，透過不同的市場策略佔據了全球介入性心臟病學市場的大量佔有率。該地區在全球介入性心臟病學市場的主導地位。例如，2021 年 9 月，雅培收購了 Walk Vascular, LLC，這是一家商業階段的醫療器材公司，擁有微創機械抽吸血栓切除系統，旨在清除周邊血塊。

同樣，2022 年 8 月，GE 醫療保健與波士頓科學公司合作，在印度提供創新的介入性心臟護理解決方案。此外，2022 年 1 月，美敦力收購了 Affero，擴大了美敦力的心臟消融產品組合。此外，2021 年 11 月，美敦力在印度推出了 Arctic Front 先進心臟冷凍消融導管技術，用於治療心房顫動。因此，資料顯示北美將在整個預測期內主導全球介入性心臟病學市場。

介入性心臟病學市場競爭格局

全球介入性心臟病學市場主要參與者包括雅培、波士頓科學公司、強生、美敦力、B.Barun Melsungen、Biosensors International Ltd.、Terumo Corporation、Biotronik SE and Co. KG、Edwards Lifesciences Corporation 和 Cook Medical Inc。正在採取各種策略，如產品發布、併購、合作夥伴關係和協作，為全球介入性心臟病學市場的成長做出貢獻。例如，2022 年 7 月，Terumo India 與 Sensible Medical Innovations 簽署了新的策略性商業分銷合作夥伴關係。

美敦力有限公司

概述 ：

美敦力公司是一家總部位於愛爾蘭的美國醫療器材公司。美敦力公司成立於1949年，總部位於美國明尼蘇達州明尼亞波利斯。美敦力負責四個不同的業務：微創治療集團、糖尿病集團、恢復治療集團以及心臟和血管集團。

產品組合：

美敦力 (Medtronic) 公司的產品組合。用於介入性心臟病學的 Endurant II 覆膜支架系統：該系統提供理想的護理，並在治療腹主動脈瘤 (AAA) 方面擁有臨床成功的歷史。只有 Endurant 系列產品是為了解決囊退化問題而開發的。

目錄

第 1 章：方法與範圍

第 2 章：市場定義與概述

第 3 章：執行摘要

第 4 章：市場動態

  • 市場影響因素
    • 促進要素
      • 心血管疾病的盛行率不斷上升
      • 老年人口不斷增加
    • 限制
      • 心臟介入治療費用高昂
      • 嚴格監管
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章：COVID-19 分析

第 7 章：按類型

  • 支架
    • 裸機
    • 藥物洗脫
    • 生物可吸收
  • 導管
    • 血管成形術
    • 指導
    • 肺動脈
    • 血管內超音波 (IVUS)
  • PTCA球囊
    • 普通的
    • 切割
    • 評分
    • 藥物洗脫
  • 影像系統
    • IVUS（血管內超音波）
    • FFR（分數流服務）
    • OCT（光學相干斷層掃描）
  • 雷射手術
  • 旋切術
  • 其他（導絲）

第 8 章：最終用戶

  • 醫院
  • 門診手術中心 (ASC)
  • 其他

第 9 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太地區其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 主要進展和策略
  • 公司股份分析
  • 產品基準化分析

第 11 章：公司簡介

  • Medtronic Plc
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務概覽
  • Abbott
  • Boston Scientific Corporation
  • Johnson & Johnson
  • B.Barun Melsungen
  • Biosensors International Ltd.
  • Terumo Corporation
  • Biotronik SE and Co KG
  • Edwards Lifesciences Corporation
  • Cook Medical Inc.(*LIST NOT EXHAUSTIVE)

第 12 章：數據M

簡介目錄
Product Code: MD312

Market Size

The Global Interventional Cardiology Market reached US$ 14.47 billion in 2023 and is expected to reach US$ 28.67 billion by 2031, growing at a CAGR of 9.1% during the forecast period 2024-2031.

As per the American Medical Association, interventional cardiology is a branch of medicine within cardiology that evaluates blood flow, and pressure in the coronary arteries and chambers of the heart with the help of specialized imaging and other diagnostic techniques also involves the technical procedures and medications utilized for those abnormalities impairing the functions of the cardiovascular system.

Interventional Cardiology Market Dynamics

The growing cases of cardiovascular diseases, geriatric populations, lifestyle changes, and increasing awareness about cardiovascular diseases are fueling the global interventional cardiology market growth.

The new product launches boost the global interventional cardiology market during the forecast period.

The new product launches fuel the growth of the global interventional cardiology market. For instance, in June 2021, the United States Food and Drug Administration approved Abbott's XIENCE family of stents for its one-month dual-antiplatelet therapy (DAPT) labeled for high bleeding risk (HBR) patients in the United States. Likewise, in May 2020, Philips Image Guided Therapy Corporation's Reconnaissance PV .018 OTW digital IVUS catheter was granted 510 (K) approval from the US FDA. Similarly, in March 2021, Medtronic was granted product approval from the United States Food and Drug Administration for its Harmony Transcatheter Pulmonary Valve (TPV), the first minimally invasive therapy for the treatment of patients with a typical type of congenital heart defect of the right ventricle (RV), one of four chambers of the heart, which makes it difficult for blood to travel from the heart to the lungs.

Furthermore, in June 2021, Amplatzer Piccolo Occluder from Abbott was launched in India. It is the world's first medical device for implantation in the tiniest babies (weighing as little as 700 gms) with a minimally invasive procedure for treating patent ductus arteriosus, or PDA. Moreover, in July 2021, MedAlliance, a privately held medical technology company, launched two high-performance balloons, ORIGIN SC and ORIGIN NC, for vessel preparation for patients suffering from life-threatening coronary and peripheral arterial disease. Thus, the new product launches will drive the global interventional cardiology market during the forecast period.

The stringent regulations and high costs hinder the global interventional cardiology market growth.

However, the high cost of cardiological intervention and stringent regulations will hamper the global interventional cardiology market during the forecast period. For instance, the U.S. FDA is revising two guidance documents for vendors inventing new coronary, peripheral, and neurovascular guidewires. The FDA reported the draft documents in June 2018 and is yet to gather comments on one of the documents. These documents are expected to cover the performance testing, recommended labeling, and lubricious coatings, which will provide industry and FDA staff with suggestions on the least tyrannical means of evaluating the performance of catheters, guidewires, and delivery systems submitted in premarket approval applications (PMAs) or 510(k) premarket notifications. Furthermore, the average cost of percutaneous coronary intervention for chronic total occlusions was $14,946 +- 7,699, leaving a majority of the population unable to get it performed, thus slowing the global interventional cardiology market growth during the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic hurt the global interventional cardiology market since, during the pandemic, there was a large downfall in interventional cardiology procedures. For instance, the British Cardiovascular Interventional society performed a retrospective analysis of all percutaneous coronary interventions (PCI) performed in the United Kingdom during the lockdown imposed by the pandemic in comparison with PCI volumes in the pre-pandemic period.

The retrospective analysis concluded that there was 49% less PCI, with stable angina being hit the hardest, showing a 66% reduction, while the PCI for ST-elevation MI (STEMI) was down by 33%. Furthermore, the pandemic changed people's perspective toward healthy lifestyle choices, which caused a reduction in the cases of cardiovascular diseases, therefore impacting global interventional cardiology negatively.

Interventional Cardiology Market Segmentation Analysis

The stents are predicted to have a high demand during the forecast period (2024-2031).

The stents are expected to dominate the global interventional cardiology market during the forecast period (2024-2031), owing to the new introductions and product approvals in the global interventional cardiology market. For instance, in August 2021, SINOMED launched its HT Supreme Drug-Eluting Stent (DES) in Europe through the first commercial implantation at University Hospital Galway in partnership with the National University of Ireland Galway (NUI Galway). Likewise, in May 2022, the United States Food and Drug Administration (FDA) approved Medtronic plc's Onyx Frontier drug-eluting stent (DES). Onyx Frontier DES leverages the same stent platform as Resolute Onyx DES and with an enhanced delivery system.

Similarly, in January 2021, the FDA approved the Synergy Megatron Drug Eluting stent from Boston Scientific, designed to treat large proximal near the aorta. Furthermore, in May 2021, the CE mark was received by a novel polymer-free self-expanding Amphilimus eluting stent, NiTiDES, from form Alvimedica for superficial femoral artery (SFA) lesions. Therefore, from the above data, stents are anticipated to dominate the global interventional cardiology market throughout the forecast period.

Interventional Cardiology Market Geographical Share

North America is predicted to command the global interventional cardiology market.

North America is estimated to hold a large market over the forecast period (2023-2031) owing to the rising cases of cardiovascular diseases and the presence of key market players in this region. According to the CDC, a U.S. American dies every 34 seconds because of cardiovascular disease. In 2020, cardiovascular disease caused over 697,000 deaths. Furthermore, the existence of key market players such as Abbott, Edwards Lifesciences Corporation, Boston Scientific Corporation, Johnson & Johnson, Medtronic, and Cook Medical Inc., holding large shares of the global interventional cardiology market through different market strategies, are based in the United States, ensures the dominance of this region over the global interventional cardiology market. For instance, in September 2021, Abbott acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots.

Similarly, in August 2022, GE Healthcare collaborated with Boston Scientific to provide innovative interventional cardiac care solutions in India. Furthermore, in January 2022, Medtronic acquired Affero expanding Medtronic's cardiac ablation portfolio. Also, in November 2021, Medtronic launched Arctic Front Advanced Cardiac Cryoablation Catheter Technology for treating Atrial Fibrillation in India. Thus, the data shows North America will dominate the global interventional cardiology market throughout the forecast period.

Interventional Cardiology Market Competitive Landscape

The major global interventional cardiology market players are Abbott, Boston Scientific Corporation, Johnson & Johnson, Medtronic, B.Barun Melsungen, Biosensors International Ltd., Terumo Corporation, Biotronik SE and Co. KG, Edwards Lifesciences Corporation and Cook Medical Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the interventional cardiology market globally. For instance, in July 2022, Terumo India signed a new strategic commercial distribution partnership with Sensible Medical Innovations.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. for interventional cardiology contains Endurant II Stent Graft Systems: Which provides the ideal of care with a history of clinical success in treating abdominal aortic aneurysms (AAA). Only the Endurant family of products was developed to address sac regression.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Prevalence of Cardio-vascular diseases
      • 4.1.1.2. Growing Geriatric Population
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Cardiological Intervention Procedures
      • 4.1.2.2. Stringent Regulation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Stents
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
      • 7.2.2.1. Bare-Metal
      • 7.2.2.2. Drug-eluting
      • 7.2.2.3. Bio-absorbable
  • 7.3. Catheters
    • 7.3.1. Angioplasty
    • 7.3.2. Guiding
    • 7.3.3. Pulmonary Artery
    • 7.3.4. Intravascular Ultrasound (IVUS)
  • 7.4. PTCA balloons
    • 7.4.1. Normal
    • 7.4.2. Cutting
    • 7.4.3. Scoring
    • 7.4.4. Drug-eluting
  • 7.5. Image Systems
    • 7.5.1. IVUS (intravascular Ultrasound)
    • 7.5.2. FFR (Fractional Flow Service)
    • 7.5.3. OCT (Optical coherence Tomography)
  • 7.6. Laser Procedures
  • 7.7. Atherectomy
  • 7.8. Others (Guidewires)

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Hospitals
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. Ambulatory Surgical Centers (ASCs)
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Company Profiles

  • 11.1. Medtronic Plc
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Abbott
  • 11.3. Boston Scientific Corporation
  • 11.4. Johnson & Johnson
  • 11.5. B.Barun Melsungen
  • 11.6. Biosensors International Ltd.
  • 11.7. Terumo Corporation
  • 11.8. Biotronik SE and Co KG
  • 11.9. Edwards Lifesciences Corporation
  • 11.10. Cook Medical Inc.(*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us